Midi Health, one of the fastest-growing virtual clinics dedicated to women navigating midlife, is expanding access to testosterone hormone therapy, a treatment that plays a critical role in maintaining women’s libido, energy, mood, and cognitive function following a surge in demand across its 200,000+ patient network.
Through its revamped website and faster booking process, Midi now makes it easier for women to connect with expert clinicians, complete required lab work, and receive safe, personalized care in a matter of weeks using a topical cream that allows for precise, individualized, and adjustable dosing - avoiding pellets that can’t be easily modified once implanted.
With no FDA-approved testosterone therapies for women in the U.S., many women are forced to rely on off-label or compounded male formulations - a stark contrast to countries like Australia and the United Kingdom, which have safely prescribed testosterone to women for decades. Midi is addressing this gap by creating a formulation designed specifically for women and making it accessible through clinician-led care that helps to restore testosterone, using physiologic dosing that maximizes benefits while minimizing side effects.
“Women have been excluded from testosterone therapy for decades. The fact there’s still no FDA-approved option for women in the U.S. is a glaring inequity that leaves millions suffering in silence,” said Joanna Strober, chief executive officer and co-founder of Midi Health. “We are disrupting that system by expanding access and fighting for the change women deserve. Our offering provides ongoing care from clinicians who personalize treatment plans and check in regularly to ensure women are getting the results and support they need, all while being covered by insurance. We’re on a mission to make this process easier for women and remove the laborious hoops patients have to go through to get access to testosterone hormone therapy.”
"One of the biggest hurdles we face isn't clinical, it's the persistent myth that testosterone is a ‘male hormone’ and irrelevant for women’s health,” said Dr. Kathleen Jordan, chief medical officer at Midi Health. “The reality is that for women who struggle with symptoms that other treatments don't fully address, testosterone is an evidence-based therapy that can provide the final piece of the puzzle. Many women can experience life-changing outcomes: a return to their baseline energy and mental clarity, and a renewed sense of vitality. My hope is that by making this treatment accessible and supported by personalized, expert clinical oversight, we can finally demystify it and ensure no woman has to struggle silently anymore."
Covered by major insurers, Midi has licensed and trained providers to support women with testosterone therapy in 12 of its largest states with nationwide expansion planned as individual state regulations allow. The company will also be hosting “T Parties” around the country to educate women about testosterone therapy and hormone health and provide an intimate setting to have open conversations with experts and peers.
To learn more about Midi’s testosterone therapy, visit https://www.joinmidi.com/store/testosterone.
About Midi Health
Founded in 2021 by Joanna Strober and Sharon Meers, Midi Health is the one of the fastest growing virtual care clinics in the United States focused on women navigating and preparing for midlife, with a special focus on hormone health, peri/menopause management, longevity, and aging well. With holistic treatment protocols created by world-class medical experts in hormone health, delivered by clinicians trained in women's midlife health, Midi Health provides patients with personalized care plans that include hormonal and non-hormonal medications, supplements, lifestyle coaching and more. All services are covered by insurance, and conveniently accessible through telehealth visits and 24/7 messaging.
Book your visit at www.joinmidi.com and learn more at www.joinmidi.com/blog.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030286029/en/
Contacts
PR:
midi@jbc-pr.com